Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049504 · ClinicalTrials.gov registry record · Phase 2
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT00049504 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 53 participants.
The verdict
NCT00049504, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
This phase II trial studies how well giving fludarabine phosphate, cyclophosphamide, tacrolimus, mycophenolate mofetil and total-body irradiation together with a donor bone marrow transplant works in treating patients with high-risk hematologic cancer. Giving low doses of chemotherapy, such as fludarabine phosphate and cyclophosphamide, and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer cells by stopping them from dividing or killing them. Giving cyclophosphamide after transplant may also stop the patient's immune system from rejecting the donor's bone marrow stem cells. The donated stem cells may replace the patient's immune system cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus and mycophenolate mofetil after the transplant may stop this from happening
Interventions
- DRUG cyclophosphamide
- GENETIC polymerase chain reaction
- DRUG fludarabine phosphate
- DRUG tacrolimus
- DRUG mycophenolate mofetil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2002-01 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00049504
The ClinicalTrials.gov registry entry for NCT00049504 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00049504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00049504 about?
NCT00049504 is a clinical study titled "Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer". This phase II trial studies how well giving fludarabine phosphate, cyclophosphamide, tacrolimus, mycophenolate mofetil and total-body irradiation together with a donor bone marrow transplant works in treating patients with high-risk hematologic cancer. Giving low doses of chemotherapy, such as fluda...
What is the current status of trial NCT00049504?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2002-01. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00049504?
The interventions under investigation include: cyclophosphamide (DRUG), polymerase chain reaction (GENETIC), fludarabine phosphate (DRUG), tacrolimus (DRUG), mycophenolate mofetil (DRUG).
Who is sponsoring clinical trial NCT00049504?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.